Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
Trial details
- Registry ID
- NCT06325566
- Phase
- Phase 3
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back PainNCT06325566 | MESO | Phase 3 | Active not recruiting | 2027-07Estimated |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host DiseaseNCT07568535 | MESO | Phase 3 | Not yet recruiting | 2028-02-28Estimated |
NCT06325566 · Mesoblast, Ltd.
Oct 2026
Jul 2027
Recruiting
Active not recruiting